The clinical decision support content developer is integrating genetic testing information into its knowledgebase to assist physicians at the point of care.
Despite the step-up in FDA action against labs offering PGx tests, the success of these programs suggests that access to them isn't being stifled as some feared.
The companies will offer customers a way to mine 23andMe's customer base for subjects with specific genetic or clinical features, and design and conduct a trial around them.
As part of the shift, DNA.Land, which was run as an academic research project, will delete all data by the end of the month and ask customers to resubmit it.
The Cancer Journal documented 25 cases where inappropriate tests were ordered, variants were interpreted incorrectly, and wrong results were reported to patients.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.
